Secondary analysis of RESHAPE-HF2 (505 patients with heart failure and moderate-to-severe secondary mitral regurgitation): M-TEER's effect on CV death or HF hospitalisation did not differ by baseline KCCQ-CSS tertile (P-trend=0.53); it improved health status vs medical therapy.
Secondary analysisn = 505
Butler et al. Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial